Quintrio
Home

OPHTHALMIC GOODS

Staar Surgical Co

STAA

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.

Last trade $25.54
Day change -$0.47 (-1.81%)
Day range $25.22 – $26.49
Volume 189,883
Market cap $1.31B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.31B
Price / earnings
2,463.68×
Price / book
3.47×
Price / sales
3.98×
EV / sales
3.57×
EV / EBITDA
75.99×

Profitability

Earnings per share
$0.01
Return on assets
0.11%
Return on equity
0.14%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.68×
Quick ratio
4.08×
Cash ratio
1.77×

Cash flow

Price / cash flow
61.03×
Price / free cash flow
73.16×
Free cash flow
$17.85M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for STAA, quarterly periods
Line itemQ3 FY2026 Oct 2, 2026Q2 FY2026 Jul 3, 2026Q1 FY2026 Apr 3, 2026Q4 FY2025 Jan 2, 2026Q3 FY2025 Sep 26, 2025Q2 FY2025 Jun 27, 2025Q1 FY2025 Mar 28, 2025Q4 FY2024 Dec 27, 2024
Revenue$83.41M$93.54M$93.52M$57.8M$94.73M$44.32M$42.59M$48.95M
Cost of revenue$24.28M$23.81M$24.66M$14.06M$16.86M$11.52M$14.58M$17.3M
Gross profit$59.14M$69.73M$68.86M$43.74M$77.88M$32.8M$28.01M$31.65M
Selling, general and administrative$43.22M$49.68M$41.53M$45.43M$44.22M$47.25M$51.4M$49.79M
Research and development$10.46M$9.94M$9.93M$9.24M$9.21M$10.26M$11.34M$9.77M
Total operating expenses$53.68M$59.63M$60.88M$66.58M$59.39M$62.76M$85.41M$59.56M
Operating income$5.46M$10.1M$7.98M-$22.84M$18.49M-$29.96M-$57.4M-$27.91M
Interest expense$1.18M$0$907K$0$790K$0$1.37M$0
Income before taxes$6.98M$11.02M$8.22M-$20.65M$18.79M-$25.92M-$54.49M-$30.33M
Income taxes$1.41M$2.97M$3.01M-$2.34M$9.91M-$9.1M-$275K$3.89M
Net income$5.58M$8.06M$5.21M-$18.31M$8.88M-$16.81M-$54.21M-$34.23M
Net income attributable to common shareholders$5.58M$8.06M$5.21M-$18.31M$8.88M-$16.81M-$54.21M-$34.23M
EBITDA$8.84M$13.44M$12.87M-$19.73M$20.62M-$22.59M-$32.35M-$25.54M
Basic earnings per share$0.11$0.16$0.10-$0.37$0.18-$0.34-$1.10-$0.70
Diluted earnings per share$0.11$0.16$0.10-$0.37$0.18-$0.34-$1.10-$0.71

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Merit Medical (MMSI) Q3 Earnings and Revenues Beat Estimates

Merit Medical (MMSI) reported Q3 2026 earnings of $1.12 per share, beating consensus estimates of $1.04, with revenues of $416.24 million exceeding expectations by 1.43%. However, the stock has underperformed the S&P 500 this year, gaining 4.6% versus the market's 13.1%. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Meanwhile, peer Staar Surgical (STAA) is expected to report declining earnings and revenues for the same quarter.

The Motley Fool

Why Staar Surgical Zoomed Almost 8% Higher on Tuesday

Staar Surgical stock surged nearly 8% after Stifel analyst Thomas Stephan upgraded the company to 'buy' from 'hold' and raised the price target to $31 from $28. The upgrade was driven by expectations of higher sales in the second half of 2026, particularly for the company's surgically implanted lenses in China, and recognition of Staar's potential as an acquisition target and product developer.

The Motley Fool

Why Staar Surgical Stock Soared Today

Staar Surgical announced a $50 million share buyback program authorized by its board, causing the stock to surge 7.5% on Friday. The company's CEO cited confidence in the business, strong balance sheet, and ample free cash flow, noting that Staar is substantially undervalued. Recent fundamentals support the move, with the company more than doubling net sales year-over-year in Q2, driven by growth in China, and achieving profitability with nearly $149 million in cash.

Benzinga

Why Did STAAR Surgical (STAA) Stock Jump 20% After Hours?

STAAR Surgical (NASDAQ: STAA) surged 20% in after-hours trading after reporting Q1 2026 preliminary net sales of over $90 million, more than double the $42.6 million from the prior year. Growth was driven primarily by China and the Americas with double-digit expansion, while higher sales and cost streamlining are expected to boost adjusted EBITDA. However, the company faces headwinds in the Middle East, Europe, Africa, and Asia-Pacific due to geopolitical and macroeconomic pressures, and provided no forward guidance citing volatile global conditions.

Benzinga

LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review

Alcon has terminated its merger agreement with LENSAR, a laser solutions company, after prolonged regulatory review by the Federal Trade Commission made the deal unattractive. The acquisition, originally agreed upon in March 2025 at $14.00 per share, faced extended delays and opposition. LENSAR shares plunged 25.44% in premarket trading to $7.65, hitting a new 52-week low.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.